Skip to main content
Log in

Positioning of Inflammatory Biomarkers in the Heart Failure Landscape

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

The clinical syndrome of heart failure is characterized by a systemic inflammatory response that contributes to end organ damage in the heart and circulation and can thus lead to worsening heart failure. The ensemble of inflammatory mediators that have been detected in heart failure patients include pro-inflammatory cytokines and their cognate receptors, as well as molecules secreted/released by macrophages (galectin-3 and pentraxin-3). Inflammatory biomarkers correlate with disease severity and prognosis across the broad spectrum of heart failure syndromes. Given the proliferation of new biomarkers that predict disease severity and prognosis in heart failure, it is reasonable to ask whether there is a current role for measuring inflammatory mediators in heart failure. This review will attempt to address this question, as well as review several novel approaches that have utilized inflammatory biomarkers to enhance risk stratification and prognosis in heart failure patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Askevold, E. T., Nymo, S., Ueland, T., Gravning, J., Wergeland, R., Kjekshus, J., et al. (2013). Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation Heart Failure, 6, 91–98.

    Article  PubMed  CAS  Google Scholar 

  2. Bozkurt, B., Mann, D. L., & Deswal, A. (2010). Biomarkers of inflammation in heart failure. Heart Failure Reviews, 15, 331–341.

    Article  PubMed  CAS  Google Scholar 

  3. Chin, B. S., Conway, D. S., Chung, N. A., Blann, A. D., Gibbs, C. R., & Lip, G. Y. (2003). Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: Relationship to treatment and prognosis. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis, 14, 515–521.

    Article  CAS  Google Scholar 

  4. Deswal, A., Petersen, N. J., Feldman, A. M., Young, J. B., White, B. G., & Mann, D. L. (2001). Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation, 103, 2055–2059.

    Article  PubMed  CAS  Google Scholar 

  5. Doroudgar, S., & Glembotski, C. C. (2011). The cardiokine story unfolds: Ischemic stress-induced protein secretion in the heart. Trends in Molecular Medicine, 17, 207–214.

    Article  PubMed  CAS  Google Scholar 

  6. Dunlay, S. M., Weston, S. A., Redfield, M. M., Killian, J. M., & Roger, V. L. (2008). Tumor necrosis factor-alpha and mortality in heart failure: A community study. Circulation, 118, 625–631.

    Article  PubMed  CAS  Google Scholar 

  7. Gallucci, S., & Matzinger, P. (2001). Danger signals: SOS to the immune system. Current Opinion in Immunology, 13, 114–119.

    Article  PubMed  CAS  Google Scholar 

  8. Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S. H., Hulthe, J., Muntendam, P., et al. (2012). The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal, 164, 878–883.

    Article  PubMed  CAS  Google Scholar 

  9. Gullestad, L., Ueland, T., Vinge, L. E., Finsen, A., Yndestad, A., & Aukrust, P. (2012). Inflammatory cytokines in heart failure: Mediators and markers. Cardiology, 122, 23–35.

    Article  PubMed  CAS  Google Scholar 

  10. Ionita, M. G., Arslan, F., de Kleijn, D. P., & Pasterkamp, G. (2010). Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. Journal of Innate Immunity, 2, 307–315.

    Article  PubMed  CAS  Google Scholar 

  11. Jacobshagen, C., Belardinelli, L., Hasenfuss, G., & Maier, L. S. (2011). Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study. Clinical Cardiology, 34, 426–432.

    Article  PubMed  Google Scholar 

  12. Januzzi, J. L., Jr., Peacock, W. F., Maisel, A. S., Chae, C. U., Jesse, R. L., Baggish, A. L., et al. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Journal of the American College of Cardiology, 50, 607–613.

    Article  PubMed  CAS  Google Scholar 

  13. Kalogeropoulos, A., Georgiopoulou, V., Psaty, B. M., Rodondi, N., Smith, A. L., Harrison, D. G., et al. (2010). Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study. Journal of the American College of Cardiology, 55, 2129–2137.

    Article  PubMed  CAS  Google Scholar 

  14. Ky, B., French, B., Levy, W. C., Sweitzer, N. K., Fang, J. C., Wu, A. H., et al. (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circulation. Heart Failure, 5, 183–190.

    Article  PubMed  CAS  Google Scholar 

  15. Ky, B., French, B., McCloskey, K., Rame, J. E., McIntosh, E., Shahi, P., et al. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation. Heart Failure, 4, 180–187.

    Article  PubMed  Google Scholar 

  16. Latini, R., Gullestad, L., Masson, S., Nymo, S. H., Ueland, T., Cuccovillo, I., et al. (2012). Pentraxin-3 in chronic heart failure: The CORONA and GISSI-HF trials. European Journal of Heart Failure, 14, 992–999.

    Article  PubMed  CAS  Google Scholar 

  17. Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine, 223, 236–241.

    Article  Google Scholar 

  18. Levine, S. J. (2008). Molecular mechanisms of soluble cytokine receptor generation. The Journal of Biological Chemistry, 283, 14177–14181.

    Article  PubMed  CAS  Google Scholar 

  19. Luft, F. C. (2001). Angiotensin, inflammation, hypertension, and cardiovascular disease. Current Hypertension Reports, 3, 61–67.

    Article  PubMed  CAS  Google Scholar 

  20. Mann, D. L. (1996). Stress activated cytokines and the heart. Cytokine & Growth Factor Reviews, 7, 341–354.

    Article  CAS  Google Scholar 

  21. Mann, D. L. (2002). Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circulation Research, 91, 988–998.

    Article  PubMed  CAS  Google Scholar 

  22. Mann, D. L. (2011). The emerging role of innate immunity in the heart and vascular system: For whom the cell tolls. Circulation Research, 108, 1133–1145.

    Article  PubMed  CAS  Google Scholar 

  23. Manzano-Fernandez, S., Mueller, T., Pascual-Figal, D., Truong, Q. A., & Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. The American Journal of Cardiology, 107, 259–267.

    Article  PubMed  CAS  Google Scholar 

  24. Matsubara, J., Sugiyama, S., Nozaki, T., Sugamura, K., Konishi, M., Ohba, K., et al. (2011). Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. Journal of the American College of Cardiology, 57, 861–869.

    Article  PubMed  CAS  Google Scholar 

  25. Matsumoto, M., Tsujino, T., Lee-Kawabata, M., Naito, Y., Sakoda, T., Ohyanagi, M., et al. (2010). Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine, 49, 264–268.

    Article  PubMed  CAS  Google Scholar 

  26. Mueller, C., Laule-Kilian, K., Christ, A., Brunner-La Rocca, H. P., & Perruchoud, A. P. (2006). Inflammation and long-term mortality in acute congestive heart failure. American Heart Journal, 151, 845–850.

    Article  PubMed  Google Scholar 

  27. Navarro-Gonzalez, J. F., Mora, C., Muros, M., Jarque, A., Herrera, H., & Garcia, J. (2008). Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. Journal of Hypertension, 26, 2168–2175.

    Article  PubMed  CAS  Google Scholar 

  28. Pieske, B., Maier, L. S., Bers, D. M., & Hasenfuss, G. (1999). Ca2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium. Circulation Research, 85, 38–46.

    Article  PubMed  CAS  Google Scholar 

  29. Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., et al. (2000). Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 102, 3060–3067.

    Article  PubMed  CAS  Google Scholar 

  30. Rehman, S. U., Mueller, T., & Januzzi, J. L., Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology, 52, 1458–1465.

    Article  PubMed  CAS  Google Scholar 

  31. Reichlin, T., Socrates, T., Egli, P., Potocki, M., Breidthardt, T., Arenja, N., et al. (2010). Use of myeloperoxidase for risk stratification in acute heart failure. Clinical Chemistry, 56, 944–951.

    Article  PubMed  CAS  Google Scholar 

  32. Shah, R. V., Chen-Tournoux, A. A., Picard, M. H., van Kimmenade, R. R., & Januzzi, J. L. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 12, 826–832.

    Article  PubMed  CAS  Google Scholar 

  33. Subramanian, D., Subramanian, V., Deswal, A., & Mann, D. (2011). New predictive models of heart failure mortality using time-series measurements and ensemble models. Circulation: Heart Failure, 4, 456–462.

  34. Suzuki, S., Takeishi, Y., Niizeki, T., Koyama, Y., Kitahara, T., Sasaki, T., et al. (2008). Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. American Heart Journal, 155, 75–81.

    Article  PubMed  CAS  Google Scholar 

  35. Torre-Amione, G., Kapadia, S., Benedict, C. R., Oral, H., Young, J. B., & Mann, D. L. (1996). Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology, 27, 1201–1206.

    Article  PubMed  CAS  Google Scholar 

  36. Torre-Amione, G., Kapadia, S., Lee, J., Bies, R. D., Lebovitz, R., & Mann, D. L. (1995). Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation, 92, 1487–1493.

    Article  PubMed  CAS  Google Scholar 

  37. Tsutamoto, T., Wada, A., Ohnishi, M., Tsutsui, T., Ishii, C., Ohno, K., et al. (2004). Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. European Journal of Heart Failure, 6, 173–180.

    Article  PubMed  CAS  Google Scholar 

  38. Ueland, T., Aukrust, P., Damas, J. K., Gullestad, L., & Yndestad, A. (2006). The tumor necrosis factor superfamily in heart failure. Future Cardiology, 2, 101–111.

    Article  PubMed  CAS  Google Scholar 

  39. van Kimmenade, R. R., Januzzi, J. L., Jr., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology, 48, 1217–1224.

    Article  PubMed  Google Scholar 

  40. Vasan, R. S., Sullivan, L. M., Roubenoff, R., Dinarello, C. A., Harris, T., Benjamin, E. J., et al. (2003). Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation, 107, 1486–1491.

    Article  PubMed  CAS  Google Scholar 

  41. Villacorta, H., Masetto, A. C., & Mesquita, E. T. (2007). C-reactive protein: An inflammatory marker with prognostic value in patients with decompensated heart failure. Arquivos Brasileiros de Cardiologia, 88, 585–589.

    Article  PubMed  CAS  Google Scholar 

  42. Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation, 126, 1596–1604.

    Article  PubMed  CAS  Google Scholar 

  43. Weinberg, E. O., Shimpo, M., Hurwitz, S., Tominaga, S., Rouleau, J. L., & Lee, R. T. (2003). Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 107, 721–726.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Douglas L. Mann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartupee, J., Mann, D.L. Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. J. of Cardiovasc. Trans. Res. 6, 485–492 (2013). https://doi.org/10.1007/s12265-013-9467-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-013-9467-y

Keywords

Navigation